Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...
Pilot trial shows that a user-friendly electronic patient-reported outcome (ePRO) monitoring system significantly improves ...
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of ...
In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...
An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses historical challenges with long protocol ...
In 2025, sponsors will prioritize contract research organizations (CROs) offering complete and continuous data transparency ...
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, talks protocol submission formats and how data interoperability can support artificial intelligence.
Suvoda and Greenphire have announced an agreement to merge. The merger will unite both clinical technology vendors to offer an end-to-end platform for clinical trials. Under the terms of the agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback